AstraZeneca PLC (AZN) Given Average Rating of “Hold” by Analysts
AstraZeneca PLC (LON:AZN) has been assigned an average rating of “Hold” from the twenty-three analysts that are currently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is GBX 5,158.84 ($67.85).
Several analysts recently issued reports on the company. Investec boosted their price target on AstraZeneca PLC from GBX 4,900 ($64.45) to GBX 5,500 ($72.34) and gave the company a “buy” rating in a research note on Monday, November 6th. J P Morgan Chase & Co set a GBX 4,200 ($55.24) price target on AstraZeneca PLC and gave the company a “neutral” rating in a research note on Wednesday, August 9th. Barclays PLC restated an “overweight” rating and issued a GBX 5,500 ($72.34) price target on shares of AstraZeneca PLC in a research note on Monday, August 7th. HSBC Holdings PLC boosted their price target on AstraZeneca PLC from GBX 4,340 ($57.08) to GBX 4,380 ($57.61) and gave the company a “reduce” rating in a research note on Thursday, November 16th. Finally, Jefferies Group LLC reduced their price target on AstraZeneca PLC from GBX 4,900 ($64.45) to GBX 4,400 ($57.87) and set a “hold” rating for the company in a research note on Tuesday, August 1st.
AstraZeneca PLC (LON AZN) opened at GBX 5,018 ($66.00) on Thursday. AstraZeneca PLC has a one year low of GBX 3,996 ($52.56) and a one year high of GBX 5,520 ($72.60).
AstraZeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.